Search
- Report
Letter to the Honorable Charles B. Rangel
- Report
Letter to the Honorable Max Baucus
- Cost Estimate
Letter to the Honorable Charles B. Rangel
- Blog Post
Investment in research and development (R&D) over the past several decades has produced a wealth of valuable new drug therapies. Current and future pharmaceutical R&D will determine what drug therapies will become available, and thus will influence future health-care costs. Yesterday CBO released a brief that describes the state of investment in drug R&D and the factors that influence it.
- Report
Economic and Budget Issue Brief
- Report
- Report
Letter to the Honorable Orrin G. Hatch
- Blog Post
CBO just distributed two tables of additional analysis of the Senate Finance Committee Chairmans Mark, as amended, of the Americas Healthy Future Act of 2009. The first table updates information (originally provided in a September 22nd letter to Chairman Baucus) about the subsidies offered through insurance exchanges and enrollees payments for that coverage.
- Blog Post
Today CBO released a letter updating its analysis of the effects of proposals to limit costs related to medical malpractice (tort reform). Typical legislative proposals for tort reform have included caps on awards for noneconomic and punitive damages, rules allowing the introduction at trials of evidence about insurance payments and related sources of income, statutes of limitations on suits, and replacement of joint-and-several liability with a fair-share rule.
- Report
Letter to the Honorable Chuck Grassley